DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: 5-Fluorouracil (5-FU)
Drug: Capecitabine
Drug: Irinotecan
Drug: Cisplatin

First Posted Date: 2005-09-22

Last Posted Date: 2018-11-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 54

Registration Number: NCT00215501

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma

Early Phase 1

Completed

Conditions: Gastro-esophageal Junction Cancer
Stomach Cancer
Gastric Cancer

Interventions: Drug: Epirubicin
Drug: Cisplatin
Drug: 5-Fluorouracil (5-FU)
Procedure: Radiation

First Posted Date: 2005-09-22

Last Posted Date: 2014-07-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT00215514

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Computerized Assessment for Patients With Cancer

Phase 3

Completed

Conditions: Neoplasms

Interventions: Behavioral: ESRA-C

First Posted Date: 2005-09-19

Last Posted Date: 2015-05-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 1058

Registration Number: NCT00194493

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States

Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma

Phase 1

Completed

Conditions: Pleural Mesothelioma
Malignant Pleural Mesothelioma

First Posted Date: 2005-09-14

Last Posted Date: 2014-03-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 70

Registration Number: NCT00165555

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer
Neoplasm Metastasis

First Posted Date: 2005-09-14

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00165568

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Treatment of Acute Lymphoblastic Leukemia in Children

Phase 3

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: doxorubicin
Drug: prednisone
Drug: dexamethasone
Drug: E. coli asparaginase
Drug: vincristine
Drug: methotrexate
Drug: Leucovorin
Drug: cytarabine
Drug: Asparaginase
Drug: Methotrexate/Hydrocortisone

First Posted Date: 2005-09-14

Last Posted Date: 2013-04-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 498

Registration Number: NCT00165178

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Wide Excision Alone As Treatment for Ductal Carcinoma in Situ of the Breast

Phase 2

Active, not recruiting

Conditions: Ductal Carcinoma in Situ of the Breast

Interventions: Other: Observation

First Posted Date: 2005-09-14

Last Posted Date: 2024-12-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 158

Registration Number: NCT00165256

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

First Posted Date: 2005-09-14

Last Posted Date: 2009-07-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 53

Registration Number: NCT00165334

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors

Phase 2

Completed

Conditions: Neuroendocrine Tumor

First Posted Date: 2005-09-14

Last Posted Date: 2009-04-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 32

Registration Number: NCT00165230

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States

Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus

Phase 2

Completed

Conditions: Adenocarcinoma of Stomach
Adenocarcinoma of GE Junction
Adenocarcinoma of Esophagus

First Posted Date: 2005-09-14

Last Posted Date: 2009-04-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 32

Registration Number: NCT00165191

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy